|
|
|
|
| LEADER |
01759nam a2200265 u 4500 |
| 001 |
EB001865256 |
| 003 |
EBX01000000000000001029336 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
190504 r ||| eng |
| 020 |
|
|
|a 9789241550284
|
| 245 |
0 |
0 |
|a Guidelines on second- and third-line medicines and type of insulin for the control of blood glucose levels in non-pregnant adults with diabetes mellitus
|h Elektronische Ressource
|
| 260 |
|
|
|a Geneva
|b World Health Organization
|c 2018, [2018]
|
| 300 |
|
|
|a 1 PDF file (69 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Hypoglycemic Agents / therapeutic use
|
| 653 |
|
|
|a Hyperglycemia / drug therapy
|
| 653 |
|
|
|a Diabetes Mellitus / prevention & control
|
| 653 |
|
|
|a Insulin / therapeutic use
|
| 710 |
2 |
|
|a World Health Organization
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK532229
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The new guidelines provide public health guidance on pharmacological agents for managing hyperglycaemia in type 1 and type 2 diabetes for use in primary health-care in low-resource settings. These guidelines update the recommendations for managing hyperglycaemia in the WHO Package of Essential NCD Interventions (WHO PEN) for primary care in low-resources settings, reviewing several newer oral agents as second- and third-line treatment: dipeptidyl peptidase-4 inhibitors, sodium-glucose co-transporter 2 inhibitors and thiazolidinediones. The guidelines also present recommendations on the selection of type of insulin (analogue versus human insulin) for adults with type 1 and type 2 diabetes
|